Fig. 7: Prediction of outcomes with T-DXd using DNADX. | npj Precision Oncology

Fig. 7: Prediction of outcomes with T-DXd using DNADX.

From: Quantitative HER2 tissue and plasma profiling predicts the activity of trastuzumab deruxtecan for breast cancer

Fig. 7: Prediction of outcomes with T-DXd using DNADX.

A Description of DNADX workflow; B Outcomes with T-DXd for metastatic breast cancer according to DNADX-detected tumor fraction; C Outcomes with T-DXd for metastatic breast cancer according to DNADX subtype; D Outcomes with T-DXd for metastatic breast cancer according to the DNADX HER2 signature; E Outcomes with T-DXd for metastatic breast cancer according to HER2 IHC status in the cohort of patients with detectable tumor fraction. T-DXd trastuzumab deruxtecan, TTNT, time to next treatment, OS overall survival.

Back to article page